FDA Approved Drugs by Medical Condition

Search by medical condition for drugs approved by the Food and Drug Administration (FDA) for sale in the United States. Select the letter below that corresponds to the first letter of the medical condition you are searching for and all approved drugs classified under that category will be listed below.

Deep Vein Thrombosis

Savaysa (edoxaban) (by Daiichi Sankyo), Approved January 2015
For the treatment of deep vein thrombosis, pulmonary embolism and risk of stroke and embolism due to atrial fibrillation

Dementia

Namzaric (memantine hydrochloride extended-release + donepezil hydrochloride) (by Forest Laboratories), Approved December 2014
For the treatment of moderate to severe dementia of the Alzheimer's type

Depression

Brintellix (vortioxetine) (by Takeda Pharmaceuticals USA), Approved October 2013
For the treatment of Major Depressive Disorder

Celexa (by Forest Laboratories), Approved July 1998
Treatment for depression

Clomipramine hydrochloride (by Mylan Laboratories), Approved April 1998
Generic equivalent of Anafranil

Cymbalta (duloxetine) (by Eli Lilly), Approved August 2004
For the treatment of major depressive disorder

Effexor XR (venlafaxin HCI) (by Wyeth), Approved October 1997
Treatment of depression

Fetzima (levomilnacipran) (by Forest Laboratories), Approved July 2013
For the treatment of major depressive disorder

Lithobid (Lithium Carbonate) (by Solvay Pharmaceuticals), Approved January 1996
Treatment for manic depression

Marplan Tablets (by Roche), Approved August 1998
Treatment of Depression

Paxil CR (paroxetine hydrochloride) (by GlaxoSmithKline), Approved February 2002
Oral tablet for the treatment of depression and panic disorder

Prozac Weekly (fluoxetine HCl) (by Eli Lilly), Approved February 2001
For the treatment of depression

Remeron (Mirtazapine) (by Organon), Approved June 1996
Treatment for depression

Remeron SolTab (mirtazapine) (by Organon), Approved January 2001
Orally disintegrating tablet for the treatment of depression

Rexulti (brexpiprazole) (by Otsuka), Approved July 2015
For the treatment of depression and schizophrenia

Trazadone 150mg (by Teva Pharmaceutical), Approved May 1997
Generic equivalent of Desyrel 7

Depression (Major/Severe)

Lexapro (escitalopram oxalate) (by Forest Laboratories), Approved August 2002
An orally administered selective serotonin reuptake inhibitor useful for the treatment for major depressive disorder

Oleptro (trazodone hydrochloride) (by Labopharm), Approved February 2010
For the treatment of major depressive disorder

Rexulti (brexpiprazole) (by Otsuka), Approved July 2015
For the treatment of depression and schizophrenia

Viibryd (vilazodone hydrochloride) (by Clinical Data), Approved January 2011
For the treatment of major depressive disorder

Dermatitis, Atopic

Dupixent (dupilumab) (by Regeneron Pharmaceuticals), Approved March 2017
For the treatment of atopic dermatitis

Eucrisa (crisaborole) ointment (by Pfizer), Approved December 2016
For the treatment of atopic dermatitis

Diabetes Mellitus Types I and II

Afrezza (insulin human) Inhalation Powder (by Mannkind), Approved June 2014
For the treatment of diabetes mellitus

Glipizide Tablets (by Duramed Pharmaceuticals), Approved September 1997
Treatment for diabetes

Glucagon (by Eli Lilly), Approved October 1998
Treatment for severe hypoglycemia associated with diabetes.

Glyburide Tablets (by Mylan Laboratories), Approved July 1998.
Treatment for Diabetes Mellitus (Type II)

Humalog (insulin lispro) (by Eli Lilly), Approved June 1996
Treatment for type I and type II diabetes

Lantus (insulin glargine [rDNA origin] injection) (by Sanofi-aventis), Approved April 2000
For adults and children w/Type 1 diabetes, or adults w/Type 2 diabetes requiring basal insulin to control hyperglycemia

Lantus (insulin glargine [rDNA origin] injection) (by Sanofi-aventis), Approved April 2000
For the treatment of type I and type II diabetes mellitus in adults and pediatrics

NovoLog (insulin aspart) (by Novo Nordisk), Approved June 2000
An insulin analogue for the treatment of diabetes mellitus.

Novolog Mix 70/30 (by Novo Nordisk), Approved November 2001
Subcutaneous injection for the control of hyperglycemia, associated with type 1 and 2 diabetes

Symlin (pramlintide) (by Amylin Pharmaceuticals), Approved March 2005
For the treatment of type I and type II diabetes

Tresiba (insulin degludec injection) (by Novo Nordisk), Approved September 2015
For glycemic control in adults with diabetes mellitus

Diabetes Mellitus, Type 2

ACTOplus met (pioglitazone hydrochloride and metformin hydrochloride) (by Takeda), Approved August of 2005
For the treatment of type 2 diabetes

Adlyxin (lixisenatide) (by Sanofi Aventis), Approved July 2016
For the treatment of type II diabetes

Amaryl (Glimepiride) (by Hoechst Marion Roussel), Approved December 1995
Treatment for type II diabetes

Avandamet (rosiglitazone maleate and metformin HCl) (by GlaxoSmithKline), Approved October 2002
For improvement of glycemic control in type 2 diabetes patients

Bydureon (exenatide extended-release for injectable suspension) (by Amylin), Approved January 2012
For the improvement of glycemic control in adults with type II diabetes mellitus

Byetta (exenatide) (by Amylin/Eli Lilly), Approved April, 2005
For the adjunctive treatment of Type 2 diabetes mellitus

Cycloset, bromocriptine mesylate (by VeroScience), Approved May 2009
For the treatment of type 2 diabetes mellitus

Farxiga (dapagliflozin) (by Bristol-Myers Squibb), January of 2014
For the treatment of type II diabetes

Glyset (miglitol) (by Bayer), Approved December 1996
Treatment for Type II (non-insulin-dependent) diabetes mellitus

Invokana (canagliflozin) (by Janssen Pharmaceuticals), Approved April 2013
For the treatment of type II diabetes mellitus

Januvia (sitagliptin phosphate) (by Merck), Approved October 2006
For the treatment of type II diabetes

Jardiance (empagliflozin) (by Boehringer Ingelheim), Approved August 2014
For the treatment of type II diabetes

Jentadueto (linagliptin plus metformin hydrochloride) (by Eli Lilly), Approved February 2012
For the treatment of type II diabetes

Juvisync (sitagliptin and simvastatin) (by Merck), Approved October 2011
For the treatment of type II diabetes

Metaglip (glipizide/metformin HCl) (by Bristol-Myers Squibb), Approved October 2002
Oral tablets for the treatment of type 2 diabetes.

Nesina (alogliptin) (by Takeda), Approved January 2013
For the treatment of type II diabetes mellitus

Onglyza (saxagliptin) (by Bristol-Myers Squibb), Approved July 2009
For the treatment of type 2 diabetes mellitus

Prandin (by Novo Nordisk), Approved December 1997
Treatment for Type II diabetes

Precose (acarbose) (by Bayer), Approved September 6, 1995
Treatment for non-insulin-dependent diabetes mellitus

Qtern (dapagliflozin and saxagliptin) (by AstraZeneca), Approved February 2017
For the treatment of inadequately controlled type II diabetes

Soliqua 100/33 (insulin glargine and lixisenatide injection) (by Sanofi Aventis), Approved November 2016
For the treatment of inadequately controlled type II diabetes

Synjardy (empagliflozin and metformin hydrochloride) (by Boehringer Ingelheim), Approved August 2015
For the treatment of type II diabetes

Tanzeum (albiglutide) (by GlaxoSmithKline), Approved April 2014
For the treatment of type II diabetes mellitus

Tradjenta (linagliptin) (by Boehringer Ingelheim), Approved May 2011
For the treatment of type II diabetes

Trulicity (dulaglutide) (by Eli Lilly), Approved September 2014
To improve glycemic control in type II diabetics

Victoza (liraglutide) (by Novo Nordisk), Approved January 2010
For the treatment of type 2 diabetes mellitus

Welchol (colesevelam hydrochloride) (by Daiichi Sankyo), Approved January 2008
For the improvement of glycemic control in adults with type 2 diabetes mellitus

Xigduo XR (dapagliflozin + metformin hydrochloride) (by AstraZeneca), Approved October 2014
For glycemic control in adults with type II diabetes

Xultophy 100/3.6 (insulin degludec and liraglutide injection) (by Novo Nordisk), Approved November 2016
For the treatment of inadequately controlled type II diabetes

Diabetic Foot Ulcers

REGRANEX (becaplermin) Gel (by RW Johnson), Approved December 1997
Treatment for diabetic foot ulcers

Diabetic Gastroparesis

Metozolv ODT (metoclopramide hydrochloride) (by Salix Pharmaceuticals), Approved September of 2009
For the treatment of gastroesophageal reflux and diabetic gastroparesis

Diabetic Macular Edema

Lucentis (ranibizumab injection) (by Genentech), Approved August 2012
For the treatment of diabetic macular edema

Diet and Nutrition

Nesina (alogliptin) (by Takeda), Approved January 2013
For the treatment of type II diabetes mellitus

Dizzy/Fainting Spells

Northera (droxidopa) (by Chelsea Therapeutics), Approved February 2014
For the treatment of neurogenic orthostatic hypotension

Dry Eye Disease

Xiidra (lifitegrast) (by Shire), Approved July 2016
For the treatment of dry eye disease

Duodenal Ulcers

Prevpac (by TAP Pharmaceuticals), Approved December 1997
Treatment for duodenal ulcers

Prilosec (omeprazole)/Biaxin (clarithromycin) Combination Therapy (by Astra Merck, Abbott Laboratories), Approved April 1996
Treatment for duodenal ulcers

Dupuytren's Disease

Xiaflex (collagenase clostridium histolyticum) (by Auxilium Pharmaceuticals), Approved February 2010
For the treatment of Dupuytren’s contracture

Dyskinesias

Gocovri (amantadine) (by Adamas Pharmaceuticals), Approved August 2017
For the treatment of Parkinson's disease dyskinesia

Dystonias

Xeomin (incobotulinumtoxinA) (by Merz Pharmaceutical), Approved July 2010
For the treatment of cervical dystonia and blepharospasm